These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34919721)

  • 1. NIH Policies and Regulatory Pathways for the Advancement of Radiation Medical Countermeasures and Biodosimetry Tools to U.S. FDA Licensure.
    Taliaferro LP; DiCarlo AL; Satyamitra MM
    Radiat Res; 2021 Dec; ():. PubMed ID: 34919721
    [No Abstract]   [Full Text] [Related]  

  • 2. NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices.
    Satyamitra MM; Perez-Horta Z; DiCarlo AL; Cassatt DR; Rios CI; Price PW; Taliaferro LP
    Radiat Res; 2022 May; 197(5):533-553. PubMed ID: 35113982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Biomarkers for Radiation Biodosimetry and Medical Countermeasures Research: Current Status, Utility, and Regulatory Pathways.
    Satyamitra MM; DiCarlo AL; Hollingsworth BA; Winters TA; Taliaferro LP
    Radiat Res; 2022 May; 197(5):514-532. PubMed ID: 34879151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal Care in Radiation Medical Countermeasures Studies.
    Rios CI; Hollingsworth BA; DiCarlo AL; Esker JE; Satyamitra MM; Silverman TA; Winters TA; Taliaferro LP
    Radiat Res; 2022 Nov; 198(5):514-535. PubMed ID: 36001810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Biomarkers for Radiation Biodosimetry and Medical Countermeasures Research: Current Status, Utility, and Regulatory Pathways.
    Winters TA; Taliaferro LP; Satyamitra MM
    Radiat Res; 2022 May; 197(5):554-558. PubMed ID: 35130340
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
    Singh VK; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident.
    DiCarlo AL; Jackson IL; Shah JR; Czarniecki CW; Maidment BW; Williams JP
    Radiat Res; 2012 May; 177(5):717-21. PubMed ID: 22468704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building the strategic national stockpile through the NIAID Radiation Nuclear Countermeasures Program.
    Rios CI; Cassatt DR; Dicarlo AL; Macchiarini F; Ramakrishnan N; Norman MK; Maidment BW
    Drug Dev Res; 2014 Feb; 75(1):23-8. PubMed ID: 24648046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
    Singh VK; Garcia M; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using biodosimetry to enhance the public health response to a nuclear incident.
    Wathen LK; Eder PS; Horwith G; Wallace RL
    Int J Radiat Biol; 2021; 97(sup1):S6-S9. PubMed ID: 32909884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical countermeasures for platelet regeneration after radiation exposure. Report of a workshop and guided discussion sponsored by the National Institute of Allergy and Infectious Diseases, Bethesda, MD, March 22–23, 2010.
    DiCarlo AL; Poncz M; Cassatt DR; Shah JR; Czarniecki CW; Maidment BW
    Radiat Res; 2011 Jul; 176(1):e0001-15. PubMed ID: 21545291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of a high throughput biodosimetry test in treatment prioritization after a nuclear incident.
    Jacobs AR; Guyon T; Headley V; Nair M; Ricketts W; Gray G; Wong JYC; Chao N; Terbrueggen R
    Int J Radiat Biol; 2020 Jan; 96(1):57-66. PubMed ID: 30507310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodosimetry: A Future Tool for Medical Management of Radiological Emergencies.
    Sproull MT; Camphausen KA; Koblentz GD
    Health Secur; 2017; 15(6):599-610. PubMed ID: 29193982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective biodosimetry techniques: Focus on cytogenetics assays for individuals exposed to ionizing radiation.
    Herate C; Sabatier L
    Mutat Res Rev Mutat Res; 2020; 783():108287. PubMed ID: 32192645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new NIH and FDA medical research policies: targeting gender, promoting justice.
    Baird KL
    J Health Polit Policy Law; 1999 Jun; 24(3):531-65. PubMed ID: 10386326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MCART Consortium animal models series.
    MacVittie TJ
    Health Phys; 2012 Oct; 103(4):340-2. PubMed ID: 22929466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Radiation Syndrome and the Microbiome: Impact and Review.
    Hollingsworth BA; Cassatt DR; DiCarlo AL; Rios CI; Satyamitra MM; Winters TA; Taliaferro LP
    Front Pharmacol; 2021; 12():643283. PubMed ID: 34084131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celebrating 60 Years of Accomplishments of the Armed Forces Radiobiology Research Institute1.
    Bene BJ; Blakely WF; Burmeister DM; Cary L; Chhetri SJ; Davis CM; Ghosh SP; Holmes-Hampton GP; Iordanskiy S; Kalinich JF; Kiang JG; Kumar VP; Lowy RJ; Miller A; Naeem M; Schauer DA; Senchak L; Singh VK; Stewart AJ; Velazquez EM; Xiao M
    Radiat Res; 2021 Aug; 196(2):129-146. PubMed ID: 33979439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States medical preparedness for nuclear and radiological emergencies.
    DiCarlo AL; Homer MJ; Coleman CN
    J Radiol Prot; 2021 Dec; 41(4):. PubMed ID: 34153947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation.
    Cohen MH
    Dermatol Ther; 2003; 16(2):77-84. PubMed ID: 12919107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.